|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alba Therapeutics Corp., of Baltimore, began dosing of AT-1001, an orally administered zonulin receptor antagonist in development to treat celiac disease. The study will evaluate the safety, tolerability and pharmacokinetics of the drug in 24 normal volunteers.
o Berlex Inc., of Montville, N.J., a U.S. affiliate of Berlin-based Schering AG, said updated data from the Betaseron 16-year follow-up study have identified 331 of the 372 original patients, and found that 51 percent of the multiple sclerosis patients treated with 250 mcg of Betaseron have reported being able to walk with or without assistance, compared to 45 percent of those assigned to the placebo ...